Kim Anthony-Gonda, Alex Ray, Hang Su, Yuge Wang, Ying Xiong, Danica Lee, Ariele Block, Vanessa Chilunda, Jessica Weiselberg, Lily Zemelko, Yen Y Wang, Sarah Kleinsorge-Block, Jane S Reese, Marcos de Lima, Christina Ochsenbauer, John C Kappes, Dimiter S Dimitrov, Rimas Orentas, Steven G Deeks, Rachel L Rutishauser, Joan W Berman, Harris Goldstein, Boro Dropulić
HIV-specific chimeric antigen receptor-T cell (CAR T cell) therapies are candidates to functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV-infected cells derived from latently infected cells within the HIV reservoir. Paramount to translating such therapeutic candidates successfully into the clinic will require anti-HIV CAR T cells to localize to lymphoid tissues in the body and eliminate reactivated HIV-infected cells such as CD4+ T cells and monocytes/macrophages. Here we show that i...
November 8, 2022: JCI Insight